Laser Photonics and CMS Laser Advance Tablet Drilling Technology for High-Volume Pharmaceutical Production
Innovative Systems Enhance Drug Delivery and Strengthen Market Leadership
The TD-140, TD-70, TD-10, and TD-R&D systems address a wide range of pharmaceutical needs, from high-volume tablet drilling and marking to research and development. Designed and built at CMS Laser’s advanced laser lab and machine shop in
John Armstrong, the Executive Vice President of LPC, said: “CMS Laser holds a significant market position in the pharmaceutical industry, offering superior technologies for high-volume pill production. This lineup of tablet drilling, marking, and R&D systems is designed specifically to solve industry-specific challenges, enabling pharmaceutical leaders to deliver complex medications with confidence.”
CMS Laser’s technology delivers key advantages:
- Enhanced Drug Delivery: Precise laser drilling supports controlled API time-release, improving patient outcomes.
- Anti-Counterfeit Protection: Unique tablet markings safeguard brands and patients.
- FDA Compliance: Systems adhere to CFR-21 Part 11 standards.
-
U.S. -Based Manufacturing: CMS Laser provides solutions with components sourced in accordance with TAA and the Buy American Act. - Post-Sale Support: CMS Laser is easy to reach for support, training, and installation services.
- Operational Efficiency: Laser-based solutions optimize production.
With a legacy of serving industry giants and a strong base of repeat clients, CMS Laser, a Laser Photonics company, continues to set standards in pharmaceutical manufacturing. This aligns perfectly with LPC’s broader diversification strategy, aimed at enhancing shareholder value and building resilience in dynamic markets.
About Laser Photonics Corporation
Laser Photonics is a vertically integrated manufacturer and R&D Center of Excellence for industrial laser technologies and systems. Laser Photonics seeks to disrupt the
About CMS Laser
Control Micro Systems (CMS Laser), is a 40-year
Cautionary Note Concerning Forward-Looking Statements
This press release contains “forward-looking statements” (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended), including statements regarding the Company’s plans, prospects, potential results and use of proceeds. These statements are based on current expectations as of the date of this press release and involve a number of risks and uncertainties, which may cause results and uses of proceeds to differ materially from those indicated by these forward-looking statements. These risks include, without limitation, those described under the caption “Risk Factors” in the Registration Statement. Any reader of this press release is cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release except as required by applicable laws or regulations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250514938775/en/
Investor Relations and Media Contact:
Brian Siegel, IRC®, M.B.A.
Senior Managing Director
Hayden IR
(346) 396-8696
brian@haydenir.com
Source: Laser Photonics Corporation